Selection of Systemic Therapy: Chemotherapy and Androgen Axis Agents - Evan Yu

Selection of Systemic Therapy: Chemotherapy and Androgen Axis Agents

Evan Yu, MD compares data from the CHAARTED and GETUG-AFU 15 trials, including safety and toxicity considerations, and discusses which patients should receive docetaxel.

Evan Y. Yu, MD
Associate Professor of Medicine (Oncology)
University of Washington
Fred Hutchinson Cancer Research Center


SEE RELATED CONTENT

Insights into E3805: The CHAARTED trial - Abstract

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe